EPAC1 Inhibition Protects the Heart from Doxorubicin-Induced Toxicity
M. Mazevet, A. Belhadef, M. Ribeiro, D. Dayde, A. Llach, M. Laudette, T. Belleville, P. Mateo, M. Gressette, F. Lefebvre, J. Chen, C. Bachelot-Loza, C. Rucker-Martin, F. Lezoualch, B. Crozatier, , E. Morel
This study shows that inhibiting EPAC1 protects the heart from doxorubicin-induced toxicity without affecting its cancer-killing effects.
bioRxiv · Jun 16, 2021Pathology